Recent insights into the control of human papillomavirus (HPV) genome stability, loss, and degradation

Journal of Clinical Medicine

Volumn 4, Issue 2, 2014, Pages 204-230

  Fisher, Chris ^a  

^a NONE   (United States)

Author keywords

Antiviral; Antiviral sensitizer; HPV; MRE11; Polyamide; RTEL1; RUVBL2; TDP1; TDP2; Viral persistence

Indexed keywords

ANTIVIRUS AGENT; ATM PROTEIN; ATR PROTEIN; DNA DEPENDENT PROTEIN KINASE; INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; MRE11 PROTEIN; ONCOPROTEIN; PHOSPHODIESTERASE I; POLYAMIDE; TYROSYL DNA PHOSPHODIESTERASE 1; TYROSYL DNA PHOSPHODIESTERASE 2; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; CELL CYCLE; CELL VIABILITY; DNA DEGRADATION; DNA REPLICATION; DNA TRANSCRIPTION; EPISOME; GENE AMPLIFICATION; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; INNATE IMMUNITY; MORBIDITY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION; VIRUS GENOME; VIRUS REPLICATION; WART VIRUS;

EID: 85067220148     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4020204     Document Type: Review

References (164)

1. Chen, H.C.; Schiffman, M.; Lin, C.Y.; Pan, M.H.; You, S.L.; Chuang, L.C.; Hsieh, C.Y.; Liaw, K.L.; Hsing, A.W.; Chen, C.J. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J. Natl. Cancer Inst. 2011, 103, 1387–1396.
2. Bodily, J.; Laimins, L.A. Persistence of human papillomavirus infection: Keys to malignant progression. Trends Microbiol. 2011, 19, 33–39.
3. Woodman, C.B.; Collins, S.I.; Young, L.S. The natural history of cervical HPV infection: Unresolved issues. Nat. Rev. Cancer 2007, 7, 11–22.
4. Edwards, T.G.; Helmus, M.J.; Koeller, K.; Bashkin, J.K.; Fisher, C. Human papillomavirus episome stability is reduced by aphidicolin and controlled by DNA damage response pathways. J. Virol. 2013, 87, 3979–3989.
5. Edwards, T.G.; Koeller, K.J.; Slomczynska, U.; Fok, K.; Helmus, M.; Bashkin, J.K.; Fisher, C. HPV episome levels are potently decreased by pyrrole-imidazole polyamides. Antivir. Res.2011, 91, 177–186.
6. Edwards, T.G.; Vidmar, T.J.; Koeller, K.; Bashkin, J.K.; Fisher, C. DNA damage repair genes controlling human papillomavirus (HPV) episome levels under conditions of stability and extreme instability. PLoS One 2013, 8, e75406.
7. Nagata, S. DNA degradation in development and programmed cell death. Annu. Rev. Immunol. 2005, 23, 853–875.
8. Harper, J.W.; Elledge, S.J. The DNA damage response: Ten years after. Mol. Cell 2007, 28, 739–745.
9. Yan, N.; Regalado-Magdos, A.D.; Stiggelbout, B.; Lee-Kirsch, M.A.; Lieberman, J. The cytosolic exonuclease trex1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol.2010, 11, 1005–1013.
10. Laguette, N.; Bregnard, C.; Hue, P.; Basbous, J.; Yatim, A.; Larroque, M.; Kirchhoff, F.; Constantinou, A.; Sobhian, B.; Benkirane, M. Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell 2014, 156, 134–145.
11. Lucifora, J.; Xia, Y.; Reisinger, F.; Zhang, K.; Stadler, D.; Cheng, X.; Sprinzl, M.F.; Koppensteiner, H.; Makowska, Z.; Volz, T., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccdna. Science 2014, 343, 1221–1228.
12. Archambault, J.; Melendy, T. Targeting human papillomavirus genome replication for antiviral drug discovery. Antivir. Ther. 2013, 18, 271–283.
13. Fradet-Turcotte, A.; Archambault, J. Recent advances in the search for antiviral agents against human papillomaviruses. Antivir. Ther. 2007, 12, 431–451.
14. De Martel, C.; Ferlay, J.; Franceschi, S.; Vignat, J.; Bray, F.; Forman, D.; Plummer, M. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol.2012, 13, 607–615.
15. Zur Hausen, H. Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2002, 2, 342–350.
16. Arbyn, M.; de Sanjose, S.; Saraiya, M.; Sideri, M.; Palefsky, J.; Lacey, C.; Gillison, M.; Bruni, L.; Ronco, G.; Wentzensen, N., et al. Eurogin 2011 roadmap on prevention and treatment of HPV-related disease. Int. J. Cancer 2012, 131, 1969–1982.
17. Schiller, J.T.; Lowy, D.R. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat. Rev. Microbiol. 2012, 10, 681–692.
18. Van Doorslaer, K. Evolution of the papillomaviridae. Virology 2013, 445, 11–20.
19. Chouhy, D.; Bolatti, E.M.; Perez, G.R.; Giri, A.A. Analysis of the genetic diversity and phylogenetic relationships of putative human papillomavirus types. J. Gen. Virol.2013, 94, 2480–2488.
20. Johnson, K.M.; Kines, R.C.; Roberts, J.N.; Lowy, D.R.; Schiller, J.T.; Day, P.M. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J. Virol. 2009, 83, 2067–2074.
21. Laniosz, V.; Dabydeen, S.A.; Havens, M.A.; Meneses, P.I. Human papillomavirus type 16 infection of human keratinocytes requires clathrin and caveolin-1 and is brefeldin a sensitive. J. Virol. 2009, 83, 8221–8232.
22. Day, P.M.; Lowy, D.R.; Schiller, J.T. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 2003, 307, 1–11.
23. Schelhaas, M.; Shah, B.; Holzer, M.; Blattmann, P.; Kuhling, L.; Day, P.M.; Schiller, J.T.; Helenius, A. Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog. 2012, 8, e1002657.
24. Klucevsek, K.; Daley, J.; Darshan, M.S.; Bordeaux, J.; Moroianu, J. Nuclear import strategies of high-risk HPV18 L2 minor capsid protein. Virology 2006, 352, 200–208.
25. Florin, L.; Sapp, M.; Spoden, G.A. Host-cell factors involved in papillomavirus entry. Med. Microbiol. Immunol. 2012, 201, 437–448.
26. Kadaja, M.; Silla, T.; Ustav, E.; Ustav, M. Papillomavirus DNA replication—From initiation to genomic instability. Virology 2009, 384, 360–368.
27. Garner-Hamrick, P.A.; Fisher, C. HPV episomal copy number closely correlates with cell size in keratinocyte monolayer cultures. Virology 2002, 301, 334–341.
28. Maglennon, G.A.; McIntosh, P.; Doorbar, J. Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology 2011, 414, 153–163.
29. Doorbar, J.; Quint, W.; Banks, L.; Bravo, I.G.; Stoler, M.; Broker, T.R.; Stanley, M.A. The biology and life-cycle of human papillomaviruses. Vaccine 2012, 30, doi:10.1016/j.vaccine.2012.06.083.
30. Chiang, C.M.; Ustav, M.; Stenlund, A.; Ho, T.F.; Broker, T.R.; Chow, L.T. Viral-E1 and viral-E2 proteins support replication of homologous and heterologous papillomaviral origins. Proc. Natl. Acad. Sci. USA 1992, 89, 5799–5803.
31. Frattini, M.G.; Laimins, L.A. The role of the E1 and E2 proteins in the replication of human papillomavirus type 31b. Virology 1994, 204, 799–804.
32. Ozbun, M.A. Human papillomavirus type 31b infection of human keratinocytes and the onset of early transcription. J. Virol. 2002, 76, 11291–11300.
33. Stubenrauch, F.; Colbert, A.M.; Laimins, L.A. Transactivation by the E2 protein of oncogenic human papillomavirus type 31 is not essential for early and late viral functions. J. Virol. 1998, 72, 8115–8123.
34. Ammermann, I.; Bruckner, M.; Matthes, F.; Iftner, T.; Stubenrauch, F. Inhibition of transcription and DNA replication by the papillomavirus E8(lambda)E2C protein is mediated by interaction with corepressor molecules. J. Virol. 2008, 82, 5127–5136.
35. Lace, M.J.; Anson, J.R.; Thomas, G.S.; Turek, L.P.; Haugen, T.H. The E8 boolean and E2 gene product of human papillomavirus type 16 represses early transcription and replication but is dispensable for viral plasmid persistence in keratinocytes. J. Virol. 2008, 82, 10841–10853.
36. Hoffmann, R.; Hirt, B.; Bechtold, V.; Beard, P.; Raj, K. Different modes of human papillomavirus DNA replication during maintenance. J. Virol. 2006, 80, 4431–4439.
37. Frattini, M.G.; Lim, H.B.; Laimins, L.A. In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc. Natl. Acad. Sci. USA 1996, 93, 3062–3067.
38. Meyers, C.; Mayer, T.J.; Ozbun, M.A. Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J. Virol. 1997, 71, 7381–7386.
39. Stubenrauch, F.; Lim, H.B.; Laimins, L.A. Differential requirements for conserved E2 binding sites in the life cycle of oncogenic human papillomavirus type 31. J. Virol. 1998, 72, 1071–1077.
40. Thomas, J.T.; Hubert, W.G.; Ruesch, M.N.; Laimins, L.A. Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc. Natl. Acad. Sci. USA 1999, 96, 8449–8454.
41. Park, R.B.; Androphy, E.J. Genetic analysis of high-risk E6 in episomal maintenance of human papillomavirus genomes in primary human keratinocytes. J. Virol. 2002, 76, 11359–11364.
42. Bergvall, M.; Melendy, T.; Archambault, J. The E1 proteins. Virology 2013, 445, 35–56.
43. Fradet-Turcotte, A.; Moody, C.; Laimins, L.A.; Archambault, J. Nuclear export of human papillomavirus type 31 E1 is regulated by CDK2 phosphorylation and required for viral genome maintenance. J. Virol. 2010, 84, 11747–11760.
44. Yu, J.-H.; Lin, B.Y.; Deng, W.; Broker, T.R.; Chow, L.T. Mitogen-activated protein kinases activated the nuclear localization sequence of human papillomavirus type 11 E1 DNA helicase to promote efficient nuclear import. J. Virol. 2007, 81, 5066–5078.
45. Moody, C.A.; Fradet-Turcotte, A.; Archambault, J.; Laimins, L.A. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc. Natl. Acad. Sci. USA 2007, 104, 19541–19546.
46. Egawa, N.; Nakahara, T.; Ohno, S.-I.; Narisawa-Saito, M.; Yugawa, T.; Fujita, M.; Yamato, K.; Natori, Y.; Kiyono, T. The E1 protein of human papillomavirus type 16 is dispensable for maintenance replication of the viral genome. J. Virol. 2012, 86, 3276–3283.
47. Pittayakhajonwut, D.; Angeletti, P.C. Viral trans-factor independent replication of human papillomavirus genomes. Virol. J.2010, 7, doi:10.1186/1743-422X-7-123123.
48. Steger, G.; Corbach, S. Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. J. Virol. 1997, 71, 50–58.
49. Zobel, T.; Iftner, T.; Stubenrauch, F. The papillomavirus E8 boolean and E2C protein represses DNA replication from extrachromosomal origins. Mol. Cell Biol.2003, 23, 8352–8362.
50. McBride, A.A.; Sakakibara, N.; Stepp, W.H.; Jang, M.K. Hitchhiking on host chromatin: How papillomaviruses persist. Biochim. Biophys. Acta Gene Regul. Mech. 2012, 1819, 820–825.
51. McBride, A.A. The papillomavirus e2 proteins. Virology 2013, 445, 57–79.
52. Jeon, S.; Lambert, P.F. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: Implications for cervical carcinogenesis. Proc. Natl Acad. Sci. USA 1995, 92, 1654–1658.
53. Jeon, S.; Allen-Hoffmann, B.L.; Lambert, P.F. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 1995, 69, 2989–2997.
54. Moody, C.A.; Laimins, L.A. Human papillomavirus oncoproteins: Pathways to transformation. Nat. Rev. Cancer 2010, 10, 550–560.
55. Goodwin, E.C.; Yang, E.; Lee, C.J.; Lee, H.W.; DiMaio, D.; Hwang, E.S. Rapid induction of senescence in human cervical carcinoma cells. Proc. Natl. Acad. Sci. USA 2000, 97, 10978–10983.
56. Desaintes, C.; Demeret, C.; Goyat, S.; Yaniv, M.; Thierry, F. Expression of the papillomavirus E2 protein in hela cells leads to apoptosis. Embo J. 1997, 16, 504–514.
57. Johung, K.; Goodwin, E.C.; DiMaio, D. Human papillomavirus E7 repression in cervical carcinoma cells initiates a transcriptional cascade driven by the retinoblastoma family, resulting in senescence. J. Virol. 2007, 81, 2102–2116.
58. McLaughlin-Drubin, M.E.; Munger, K. The human papillomavirus E7 oncoprotein. Virology 2009, 384, 335–344.
59. He, W.; Staples, D.; Smith, C.; Fisher, C. Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J. Virol. 2003, 77, 10566–10574.
60. Nguyen, C.L.; Munger, K. Direct association of the HPV16 E7 oncoprotein with cyclin A/CDK2 and cyclin E/CDK2 complexes. Virology 2008, 380, 21–25.
61. Howie, H.L.; Katzenellenbogen, R.A.; Galloway, D.A. Papillomavirus E6 proteins. Virology 2009, 384, 324–334.
62. Garner-Hamrick, P.A.; Fostel, J.M.; Chien, W.M.; Banerjee, N.S.; Chow, L.T.; Broker, T.R.; Fisher, C. Global effects of human papillomavirus type 18 E6/E7 in an organotypic keratinocyte culture system. J. Virol. 2004, 78, 9041–9050.
63. Hummel, M.; Hudson, J.B.; Laimins, L.A. Differentiation-induced and constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes. J. Virol. 1992, 66, 6070–6080.
64. Ozbun, M.A.; Meyers, C. Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b. J. Virol. 1997, 71, 5161–5172.
65. Ozbun, M.A.; Meyers, C. Temporal usage of multiple promoters during the life cycle of human papillomavirus type 31b. J. Virol. 1998, 72, 2715–2722.
66. Bedell, M.A.; Hudson, J.B.; Golub, T.R.; Turyk, M.E.; Hosken, M.; Wilbanks, G.D.; Laimins, L.A. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J. Virol. 1991, 65, 2254–2260.
67. Frattini, M.G.; Lim, H.B.; Doorbar, J.; Laimins, L.A. Induction of human papillomavirus type 18 late gene expression and genomic amplification in organotypic cultures from transfected DNA templates. J. Virol. 1997, 71, 7068–7072.
68. Meyers, C.; Frattini, M.G.; Hudson, J.B.; Laimins, L.A. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 1992, 257, 971–973.
69. Banerjee, N.S.; Wang, H.-K.; Broker, T.R.; Chow, L.T. Human papillomavirus (HPV) E7 induces prolonged g(2) following s phase reentry in differentiated human keratinocytes. J. Biol. Chem.2011, 286, 15473–15482.
70. Doorbar, J. The papillomavirus life cycle. J. Clin. Virol.2005, 32 (Suppl. S1), 7–15.
71. Hong, S.Y.; Laimins, L.A. Regulation of the life cycle of HPVs by differentiation and the DNA damage response. Futur. Microbiol. 2013, 8, 1547–1557.
72. Turnell, A.S.; Grand, R.J. DNA viruses and the cellular DNA-damage response. J. Gen. Virol.2012, 93, 2076–2097.
73. McFadden, K.; Luftig, M.A. Interplay between DNA tumor viruses and the host DNA damage response. Curr. Top. Microbiol. Immunol. 2013, 371, 229–257.
74. Luftig, M. Viruses and the DNA damage response: Activation and antagonism. Annu. Rev. Virol.2014, 1, 605–625.
75. Stracker, T.H.; Usui, T.; Petrini, J.H. Taking the time to make important decisions: The checkpoint effector kinases CHK1 and CHK2 and the DNA damage response. DNA Repair (Amst) 2009, 8, 1047–1054.
76. Moody, C.A.; Laimins, L.A. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog. 2009, 5, doi:10.1371/journal.ppat.1000605.
77. Fradet-Turcotte, A.; Bergeron-Labrecque, F.; Moody, C.A.; Lehoux, M.; Laimins, L.A.; Archambault, J. Nuclear accumulation of the papillomavirus E1 helicase blocks S-phase progression and triggers an atm-dependent DNA damage response. J. Virol. 2011, 85, 8996–9012.
78. Sakakibara, N.; Mitra, R.; McBride, A. The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. J. Virol. 2011, 85, 8981–8995.
79. Gillespie, K.A.; Mehta, K.P.; Laimins, L.A.; Moody, C.A. Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers. J. Virol. 2012, 86, 9520–9526.
80. Hong, S.Y.; Laimins, L.A. The JAK-STAT transcriptional regulator, STAT-5, activates the ATM DNA damage pathway to induce HPV 31 genome amplification upon epithelial differentiation. PLoS Pathog 2013, 9, doi:10.1371/journal.ppat.1003295
81. Anacker, D.C.; Gautam, D.; Gillespie, K.A.; Chappell, W.H.; Moody, C.A. Productive replication of human papillomavirus 31 requires DNA repair factor nbs1. J. Virol. 2014, 88, 8528–8544.
82. Rockley, P.F.; Tyring, S.K. Interferon-alpha, interferon-beta and interferon-gamma therapy of anogenital human papillomavirus infections. Pharmacol. Ther.1995, 65, 265–287.
83. Turek, L.P.; Byrne, J.C.; Lowy, D.R.; Dvoretzky, I.; Friedman, R.M.; Howley, P.M. Interferon induces morphologic reversion with elimination of extrachromosomal viral genomes in bovine papillomavirus-transformed mouse cells. Proc. Natl. Acad. Sci. USA 1982, 79, 7914–7918.
84. Herdman, M.T.; Pett, M.R.; Roberts, I.; Alazawi, W.O.; Teschendorff, A.E.; Zhang, X.Y.; Stanley, M.A.; Coleman, N. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 2006, 27, 2341–2353.
85. Chang, Y.E.; Pena, L.; Sen, G.C.; Park, J.K.; Laimins, L.A. Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J. Virol. 2002, 76, 8864–8874.
86. Pett, M.R.; Herdman, M.T.; Palmer, R.D.; Yeo, G.S.; Shivji, M.K.; Stanley, M.A.; Coleman, N. Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc. Natl. Acad. Sci. USA 2006, 103, 3822–3827.
87. Stark, G.R.; Darnell, J.E. The jak-stat pathway at twenty. Immunity 2012, 36, 503–514.
88. Li, S.Y.; Labrecque, S.; Gauzzi, M.C.; Cuddihy, A.R.; Wong, A.H.T.; Pellegrini, S.; Matlashewski, G.J.; Koromilas, A.E. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with TYK2 and impairs JAK-stat activation by interferon-alpha. Oncogene 1999, 18, 5727–5737.
89. Ronco, L.V.; Karpova, A.Y.; Vidal, M.; Howley, P.M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 1998, 12, 2061–2072.
90. Hong, S.; Mehta, K.P.; Laimins, L.A. Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J. Virol. 2011, 85, 9486–9494.
91. Petersen-Mahrt, S. DNA deamination in immunity. Immunol. Rev.2005, 203, 80–97.
92. Stenglein, M.D.; Burns, M.B.; Li, M.; Lengyel, J.; Harris, R.S. Apobec3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 2010, 17, 222–229.
93. Mehta, H.V.; Jones, P.H.; Weiss, J.P.; Okeoma, C.M. IFN-alpha and lipopolysaccharide upregulate APOBEC3 mRNA through different signaling pathways. J. Immunol. 2012, 189, 4088–4103.
94. Chiu, Y.L.; Greene, W.C. The APOBEC3 cytidine deaminases: An innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 2008, 26, 317–353.
95. Vartanian, J.-P.; Guetard, D.; Henry, M.; Wain-Hobson, S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 2008, 320, 230–233.
96. Warren, C.J.; Xu, T.; Guo, K.; Griffin, L.M.; Westrich, J.A.; Lee, D.; Lambert, P.F.; Santiago, M.L.; Pyeon, D. APOBEC3A functions as a restriction factor of human papillomavirus. J. Virol. 2014, doi: 10.1128/JVI.02383-14.
97. Wang, Z.; Wakae, K.; Kitamura, K.; Aoyama, S.; Liu, G.Y.; Koura, M.; Monjurul, A.M.; Kukimoto, I.; Muramatsu, M. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J. Virol. 2014, 88, 1308–1317.
98. Liu, F.; Campagna, M.; Qi, Y.; Zhao, X.; Guo, F.; Xu, C.; Li, S.; Li, W.; Block, T.M.; Chang, J., et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccdna minichromosomes. PLoS Pathog. 2013, 9, e1003613.
99. Reiser, J.; Hurst, J.; Voges, M.; Krauss, P.; Munch, P.; Iftner, T.; Stubenrauch, F. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J. Virol. 2011, 85, 11372–11380.
100. Saikia, P.; Fensterl, V.; Sen, G.C. The inhibitory action of p56 on select functions of E1 mediates interferon’s effect on human papillomavirus DNA replication. J. Virol. 2010, 84, 13036–13039.
101. Terenzi, F.; Saikia, P.; Sen, G.C. Interferon-inducible protein, p56, inhibits HPV DNA replication by binding to the viral protein E1. Embo J. 2008, 27, 3311–3321.
102. Becker, Y.; Weinber, A. Distamycin a inhibition of epstein-barr virus replication in arginine-deprived burkitt lymphoblasts. Isr. J. Med. Sci.1972, 8, 75–78.
103. Verini, M.A.; Ghione, M. Activity of a distamycin a on vaccinia virus infection of cell cultures. Chemotherapy 1964, 9, 144–157.
104. Martinez, T.F.; Phillips, J.W.; Karanja, K.K.; Polaczek, P.; Wang, C.M.; Li, B.C.; Campbell, J.L.; Dervan, P.B. Replication stress by Py-Im polyamides induces a non-canonical ATR-dependent checkpoint response. Nucl. Acids Res.2015, 42, 11546–11559.
105. Chenoweth, D.M.; Dervan, P.B. Allosteric modulation of DNA by small molecules. Proc. Natl. Acad. Sci. USA 2009, 106, 13175–13179.
106. Chenoweth, D.M.; Dervan, P.B. Structural basis for cyclic Py-Im polyamide allosteric inhibition of nuclear receptor binding. J. Am. Chem. Soc.2010, 132, 14521–14529.
107. Hunt, R.A.; Munde, M.; Kumar, A.; Ismail, M.A.; Farahat, A.A.; Arafa, R.K.; Say, M.; Batista-Parra, A.; Tevis, D.; Boykin, D.W., et al. Induced topological changes in DNA complexes: Influence of DNA sequences and small molecule structures. Nucl. Acids Res. 2011, 39, 4265–4274.
108. Drsata, T.; Zgarbova, M.; Špačková, N.; Jurecka, P.; Sponer, J.; Lankas, F. Mechanical model of DNA allostery. J. Phys. Chem. Lett. 2014, 5, 3831–3835.
109. Moretti, R.; Donato, L.J.; Brezinski, M.L.; Stafford, R.L.; Hoff, H.; Thorson, J.S.; Dervan, P.B.; Ansari, A.Z. Targeted chemical wedges reveal the role of allosteric DNA modulation in protein-DNA assembly. ACS Chem. Biol.2008, 3, 220–229.
110. He, G.; Vasilieva, E.; Harris, G.D., Jr.; Koeller, K.J.; Bashkin, J.K.; Dupureur, C.M. Binding studies of a large antiviral polyamide to a natural HPV sequence. Biochimie 2014, 102, 83–91.
111. Koeller, K.J.; Harris, G.D.; Aston, K.; He, G.; Castaneda, C.H.; Thornton, M.A.; Edwards, T.G.; Wang, S.; Nanjunda, R.; Wilson, W.D., et al. DNA binding polyamides and the importance of DNA recognition in their use as gene-specific and antiviral agents. Med. Chem. (Los Angeles) 2014, 4, 338–344.
112. Sancar, A.; Lindsey-Boltz, L.A.; Unsal-Kacmaz, K.; Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 2004, 73, 39–85.
113. Xu, M.; Bai, L.; Gong, Y.; Xie, W.; Hang, H.; Jiang, T. Structure and functional implications of the human RAD9-HUS1-RAD1 cell cycle checkpoint complex. J. Biol. Chem. 2009, 284, 20457–20461.
114. Williams, G.J.; Lees-Miller, S.P.; Tainer, J.A. MRE11-RAD50-NBS1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks. DNA Repair (Amst) 2010, 9, 1299–1306.
115. Sartori, A.A.; Lukas, C.; Coates, J.; Mistrik, M.; Fu, S.; Bartek, J.; Baer, R.; Lukas, J.; Jackson, S.P. Human ctip promotes DNA end resection. Nature 2007, 450, 509–514.
116. Hoskins, E.E.; Morreale, R.J.; Werner, S.P.; Higginbotham, J.M.; Laimins, L.A.; Lambert, P.F.; Brown, D.R.; Gillison, M.L.; Nuovo, G.J.; Witte, D.P., et al. The fanconi anemia pathway limits human papillomavirus replication. J. Virol. 2012, 86, 8131–8138.
117. Hoskins, E.E.; Morris, T.A.; Higginbotham, J.M.; Spardy, N.; Cha, E.; Kelly, P.; Williams, D.A.; Wikenheiser-Brokamp, K.A.; Duensing, S.; Wells, S.I. Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture. Oncogene 2009, 28, 674–685.
118. Romick-Rosendale, L.E.; Lui, V.W.; Grandis, J.R.; Wells, S.I. The fanconi anemia pathway: Repairing the link between DNA damage and squamous cell carcinoma. Mutat. Res. 2013, 743–744, 78–88.
119. Dupre, A.; Boyer-Chatenet, L.; Sattler, R.M.; Modi, A.P.; Lee, J.H.; Nicolette, M.L.; Kopelovich, L.; Jasin, M.; Baer, R.; Paull, T.T., et al. A forward chemical genetic screen reveals an inhibitor of the MRE11-RAD50-NBS1 complex. Nat. Chem. Biol. 2008, 4, 119–125.
120. Garner, K.M.; Pletnev, A.A.; Eastman, A. Corrected structure of mirin, a small-molecule inhibitor of the MRE11-RAD50-NBS1 complex. Nat. Chem. Biol. 2009, 5, 129–130.
121. Carvalho, J.F.S.; Kanaar, R. Targeting homologous recombination-mediated DNA repair in cancer. Expert Opin. Ther. Targets 2014, 18, 427–458.
122. Kastan, M.B. DNA damage responses: Mechanisms and roles in human disease: 2007 g.H.A. Mol. Cancer Res.2008, 6, 517–524.
123. Kuroda, S.; Urata, Y.; Fujiwara, T. Ataxia-telangiectasia mutated and the MRE11-RAD50-NBS1 complex: Promising targets for radiosensitization. Acta Med. Okayama 2012, 66, 83–92.
124. Buis, J.; Wu, Y.P.; Deng, Y.B.; Leddon, J.; Westfield, G.; Eckersdorff, M.; Sekiguchi, J.M.; Chang, S.; Ferguson, D.O. MRE11 nuclease activity has essential roles in DNA repair and genomic stability distinct from atm activation. Cell 2008, 135, 85–96.
125. Williams, R.S.; Moncalian, G.; Williams, J.S.; Yamada, Y.; Limbo, O.; Shin, D.S.; Groocock, L.M.; Cahill, D.; Hitomi, C.; Guenther, G., et al.Mre11 dimers coordinate DNA end bridging and nuclease processing in double-strand-break repair. Cell 2008, 135, 97–109.
126. Kadaja, M.; Isok-Paas, H.; Laos, T.; Ustav, E.; Ustav, M. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog. 2009, 5, e1000397.
127. Daniel, J.A.; Pellegrini, M.; Lee, B.S.; Guo, Z.; Filsuf, D.; Belkina, N.V.; You, Z.; Paull, T.T.; Sleckman, B.P.; Feigenbaum, L., et al. Loss of atm kinase activity leads to embryonic lethality in mice. J. Cell Biol.2012, 198, 295–304.
128. Yamamoto, K.; Wang, Y.; Jiang, W.; Liu, X.; Dubois, R.L.; Lin, C.S.; Ludwig, T.; Bakkenist, C.J.; Zha, S. Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice. J. Cell Biol.2012, 198, 305–313.
129. Nitiss, J.L.; Nitiss, K.C. Tdp2: A means to fixing the ends. PLoS Genet. 2013, 9, e1003370.
130. Pommier, Y.; Huang, S.Y.; Gao, R.; Das, B.B.; Murai, J.; Marchand, C. Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). DNA Repair (Amst) 2014, 19, 114–129.
131. Pype, S.; Declercq, W.; Ibrahimi, A.; Michiels, C.; van Rietschoten, J.G.; Dewulf, N.; de Boer, M.; Vandenabeele, P.; Huylebroeck, D.; Remacle, J.E. Ttrap, a novel protein that associates with cd40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappa b activation. J. Biol. Chem. 2000, 275, 18586–18593.
132. Virgen-Slane, R.; Rozovics, J.M.; Fitzgerald, K.D.; Ngo, T.; Chou, W.; van der, H.; van Noort, G.J.; Filippov, D.V.; Gershon, P.D.; Semler, B.L. An RNA virus hijacks an incognito function of a DNA repair enzyme. Proc. Natl. Acad. Sci. USA 2012, 109, 14634–14639.
133. Koniger, C.; Wingert, I.; Marsmann, M.; Rosler, C.; Beck, J.; Nassal, M. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc. Natl. Acad. Sci. USA 2014, 111, doi:10.1073/pnas.1409986111.
134. Tosi, A.; Haas, C.; Herzog, F.; Gilmozzi, A.; Berninghausen, O.; Ungewickell, C.; Gerhold, C.B.; Lakomek, K.; Aebersold, R.; Beckmann, R., et al. Structure and subunit topology of the ino80 chromatin remodeler and its nucleosome complex. Cell 2013, 154, 1207–1219.
135. Nano, N.; Houry, W.A. Chaperone-like activity of the AAA+ proteins Rvb1 and Rvb2 in the assembly of various complexes. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2013, 368, doi:10.1098/rstb.2011.0399.
136. Vannier, J.B.; Sarek, G.; Boulton, S.J. Rtel1: Functions of a disease-associated helicase. Trends Cell Biol. 2014, 24, 416–425.
137. Uringa, E.J.; Youds, J.L.; Lisaingo, K.; Lansdorp, P.M.; Boulton, S.J. Rtel1: An essential helicase for telomere maintenance and the regulation of homologous recombination. Nucl. Acids Res.2011, 39, 1647–1655.
138. Barber, L.J.; Youds, J.L.; Ward, J.D.; McIlwraith, M.J.; OʼNeil, N.J.; Petalcorin, M.I.; Martin, J.S.; Collis, S.J.; Cantor, S.B.; Auclair, M., et al. RTEL1 maintains genomic stability by suppressing homologous recombination. Cell 2008, 135, 261–271.
139. Srivenugopal, K.S.; Ali-Osman, F. The DNA repair protein, O-6-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. Oncogene 2002, 21, 5940–5945.
140. Henken, F.E.; Wilting, S.M.; Overmeer, R.M.; van Rietschoten, J.G.; Nygren, A.O.; Errami, A.; Schouten, J.P.; Meijer, C.J.; Snijders, P.J.; Steenbergen, R.D. Sequential gene promoter methylation during hpv-induced cervical carcinogenesis. Br. J. Cancer 2007, 97, 1457–1464.
141. Craveiro, R.; Costa, S.; Pinto, D.; Salgado, L.; Carvalho, L.; Castro, C.; Bravo, I.; Lopes, C.; Silva, I.; Medeiros, R. Tp73 alterations in cervical carcinoma. Cancer Genet. Cytogenet. 2004, 150, 116–121.
142. Ye, F.; Cheng, Q.; Shen, J.; Zhou, C.; Chen, H. Mismatch repair gene MLH3 Pro844Leu and Thr942ile polymorphisms and the susceptibility to cervical carcinoma and HPV infection: A case-control study in a chinese population. PLoS One 2014, 9, e96224.
143. Famooto, A.; Almujtaba, M.; Dareng, E.; Akarolo-Anthony, S.; Ogbonna, C.; Offiong, R.; Olaniyan, O.; Wheeler, C.M.; Doumatey, A.; Rotimi, C.N., et al. RPS19 and TYMS SNPs and prevalent high risk human papilloma virus infection in nigerian women. PLoS One 2013, 8, e66930.
144. De Araujo, M.R.; Rubira-Bullen, I.R.; Santos, C.F.; Dionisio, T.J.; Bonfim, C.M.; de Marco, L.; Gillio-Tos, A.; Merletti, F. High prevalence of oral human papillomavirus infection in fanconiʼs anemia patients. Oral Dis. 2011, 17, 572–576.
145. Spangle, J.M.; Munger, K. The human papillomavirus type 16 E6 oncoprotein activates MTORC1 signaling and increases protein synthesis. J. Virol. 2010, 84, 9398–9407.
146. Surviladze, Z.; Sterk, R.T.; DeHaro, S.A.; Ozbun, M.A. Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/Mtor pathway and inhibition of autophagy. J. Virol. 2013, 87, 2508–2517.
147. De Lange, T. Protection of mammalian telomeres. Oncogene 2002, 21, 532–540.
148. Hasan, M.; Yan, N. Safeguard against DNA sensing: The role of TREX1 in HIV-1 infection and autoimmune diseases. Front. Microbiol. 2014, 5, doi:10.3389/fmicb.2014.00193.
149. Mazur, D.J.; Perrino, F.W. Identification and expression of the trex1 and trex2 cdna sequences encoding mammalian 3′-->5′ exonucleases. J. Biol. Chem.1999, 274, 19655–19660.
150. Stetson, D.B.; Ko, J.S.; Heidmann, T.; Medzhitov, R. TREX1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134, 587–598.
151. Bailey, S.L.; Harvey, S.; Perrino, F.W.; Hollis, T. Defects in DNA degradation revealed in crystal structures of trex1 exonuclease mutations linked to autoimmune disease. DNA Repair (Amst) 2012, 11, 65–73.
152. Lieberman, J. Granzyme a activates another way to die. Immunol. Rev.2010, 235, 93–104.
153. Chowdhury, D.; Beresford, P.J.; Zhu, P.; Zhang, D.; Sung, J.S.; Demple, B.; Perrino, F.W.; Lieberman, J. The exonuclease TREX1 is in the set complex and acts in concert with NM23-H1 to degrade DNA during granzyme a-mediated cell death. Mol. Cell 2006, 23, 133–142.
154. Schwarz, E.; Freese, U.K.; Gissmann, L.; Mayer, W.; Roggenbuck, B.; Stremlau, A.; Hausen, H.Z. Structure and transcription of human papillomavirus sequences in cervical-carcinoma cells. Nature 1985, 314, 111–114.
155. Bernard, B.A.; Bailly, C.; Lenoir, M.C.; Darmon, M.; Thierry, F.; Yaniv, M. The human papillomavirus type-18 (HPV18) E2 gene-product is a repressor of the HPV18 regulatory region in human keratinocytes. J. Virol. 1989, 63, 4317–4324.
156. Thierry, F.; Howley, P.M. Functional-analysis of E2-mediated repression of the HPV18 p105 promoter. New Biol. 1991, 3, 90–100.
157. Choo, K.B.; Pan, C.C.; Han, S.H. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: Preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 1987, 161, 259–261.
158. Smith, P.P.; Friedman, C.L.; Bryant, E.M.; McDougall, J.K. Viral integration and fragile sites in human papillomavirus-immortalized human keratinocyte cell lines. Genes Chromosom. Cancer 1992, 5, 150–157.
159. Thorland, E.C.; Myers, S.L.; Gostout, B.S.; Smith, D.I. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 2003, 22, 1225–1237.
160. Durkin, S.G.; Glover, T.W. Chromosome fragile sites. Annu. Rev. Genet.2007, 41, 169–192.
161. Jang, M.K.; Shen, K.; McBride, A.A. Papillomavirus genomes associate with brd4 to replicate at fragile sites in the host genome. PLoS Pathog. 2014, 10, e1004117.
162. Matzner, I.; Savelyeva, L.; Schwab, M. Preferential integration of a transfected marker gene into spontaneously expressed fragile sites of a breast cancer cell line. Cancer Lett.2003, 189, 207–219.
163. Yu, T.; Ferber, M.J.; Cheung, T.H.; Chung, T.K.; Wong, Y.F.; Smith, D.I. The role of viral integration in the development of cervical cancer. Cancer Genet. Cytogenet. 2005, 158, 27–34.
164. Winder, D.M.; Pett, M.R.; Foster, N.; Shivji, M.K.; Herdman, M.T.; Stanley, M.A.; Venkitaraman, A.R.; Coleman, N. An increase in DNA double-strand breaks, induced by Ku70 depletion, is associated with human papillomavirus 16 episome loss and de novo viral integration events. J. Pathol. 2007, 213, 27–34.